Full text is available at the source.
Mitigating Blue-Light Risk in Display-Based Digital Therapeutics: A Practical Framework to Support Clinical Efficacy
Reducing Blue Light Risks in Screen-Based Digital Treatments: A Practical Guide to Improve Clinical Benefits
AI simplified
Abstract
Display-driven optical stimuli may influence therapeutic efficacy by affecting melatonin levels and circadian rhythms.
- Blue light exposure, particularly in the 450-480 nm range during the evening, is linked to melatonin suppression.
- Melanopsin-mediated pathways in the retina are associated with disruptions in circadian timing.
- Circadian disruption has potential downstream effects on mood, cognition, cardiovascular health, and metabolism.
- Increased exposure to blue light may correlate with a higher risk of cancer and skin damage.
- Distinct hazards are identified between retinal photochemical risk and circadian-disruptive effects based on light wavelength.
- Mitigation strategies include engineering display spectrums, using optical filters, and implementing software controls for optimal therapeutic use.
AI simplified